Waters ( (WAT) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Waters shares came under pressure as investors questioned how quickly new diagnostics will translate into meaningful revenue. The company reported that the U.S. FDA cleared its Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, a move that expands access to cervical cancer screening and could support longer-term growth expectations.
While the market reaction was negative in the short term, some analysts noted that successful rollout of these at-home screening tools may eventually prompt upward revisions to longer-range forecasts. For now, however, traders appear focused on execution risks and adoption timelines, tempering enthusiasm despite the positive regulatory milestone.
More about Waters
YTD Price Performance: -19.07%
Average Trading Volume: 1,133,879
Technical Sentiment Signal: Sell
Current Market Cap: $30.15B
For further insights into WAT stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.